Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1324890rdf:typepubmed:Citationlld:pubmed
pubmed-article:1324890lifeskim:mentionsumls-concept:C0004112lld:lifeskim
pubmed-article:1324890lifeskim:mentionsumls-concept:C0033532lld:lifeskim
pubmed-article:1324890lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:1324890lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:1324890pubmed:issue1lld:pubmed
pubmed-article:1324890pubmed:dateCreated1992-9-30lld:pubmed
pubmed-article:1324890pubmed:abstractTextAccumulating evidence has revealed that astrocytes are potential targets for various neurotransmitters. Here we investigated the effects of prostaglandins (PGs) on signal transduction in purified primary cultures of rat type-1 and type-2 astrocytes. PGF2 alpha, PGD2, and 9 alpha,11 beta-PGF2, a metabolite of PGD2 and a stereoisomer of PGF2 alpha, evoked a rapid rise in the intracellular Ca2+ concentration ([Ca2+]i) in type-1, but not in type-2, astrocytes. STA2, a stable analogue of thromboxane A2, was less effective, and PGE2 showed little effect. The PG-induced rise in [Ca2+]i was not blocked by an antagonist of either PGD2 receptor or thromboxane A2 receptor. PGF2 alpha and 9 alpha,11 beta-PGF2 stimulated rapid formation of inositol trisphosphate followed by inositol bisphosphate and inositol monophosphate. On the other hand, PGE2 increased the intracellular level of cyclic AMP in type-2 astrocytes, rather than in type-1 astrocytes. The potency of PGs for cyclic AMP formation was in the following order: PGE2 greater than PGE1 greater than or equal to STA2 much greater than iloprost, a stable analogue of PGI2. PGD2 and PGF2 alpha had no effect on cyclic AMP formation. These results demonstrate that type-1 astrocytes preferentially express PGF2 alpha receptors, the activation of which leads to phosphoinositide metabolism and [Ca2+]i elevation, whereas type-2 astrocytes possess PGE receptors that are linked to cyclic AMP formation.lld:pubmed
pubmed-article:1324890pubmed:languageenglld:pubmed
pubmed-article:1324890pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:citationSubsetIMlld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1324890pubmed:statusMEDLINElld:pubmed
pubmed-article:1324890pubmed:issn0894-1491lld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:ItoSSlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:HayaishiOOlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:GilesHHlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:FukuiHHlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:WadaHHlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:InagakiNNlld:pubmed
pubmed-article:1324890pubmed:authorpubmed-author:SugamaKKlld:pubmed
pubmed-article:1324890pubmed:issnTypePrintlld:pubmed
pubmed-article:1324890pubmed:volume6lld:pubmed
pubmed-article:1324890pubmed:ownerNLMlld:pubmed
pubmed-article:1324890pubmed:authorsCompleteYlld:pubmed
pubmed-article:1324890pubmed:pagination67-74lld:pubmed
pubmed-article:1324890pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:meshHeadingpubmed-meshheading:1324890-...lld:pubmed
pubmed-article:1324890pubmed:year1992lld:pubmed
pubmed-article:1324890pubmed:articleTitleType-1 and type-2 astrocytes are distinct targets for prostaglandins D2, E2, and F2 alpha.lld:pubmed
pubmed-article:1324890pubmed:affiliationDepartment of Cell Biology, Osaka Bioscience Institute, Japan.lld:pubmed
pubmed-article:1324890pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1324890pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1324890lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1324890lld:pubmed